A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Seliciclib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms APPRAISE
- Sponsors Cyclacel Pharmaceuticals
- 21 Dec 2010 Primary endpoint 'Progression-free-survival' has not been met, according to a Cyclacel Pharmaceuticals media release.
- 21 Dec 2010 Top-line results reported in a Cyclacel Pharmaceuticals media release.
- 05 Aug 2010 Top-line results are expected in 2010, according to a Cyclacel Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History